Hypoparathyroidism Treatment Market Report Scope & Overview:

The Hypoparathyroidism Treatment Market was valued at USD 856 Million in 2025 and is expected to reach USD 1,530 Million by 2035, growing at a CAGR of 5.98% from 2026-2035.

The Hypoparathyroidism Treatment Market is driven by factors such as the rising diagnosis of hypoparathyroidism, growing awareness of rare endocrine diseases, and continuous innovations in the field of hormone replacement therapy. Improved awareness among physicians and advances in calcium and parathyroid hormone testing have been aiding in the identification of new cases, which is driving treatment demands. Innovations in the field of recombinant and long-lasting parathyroid hormone therapies have helped improve the scope for treatment of inadequately controlled patients under traditional calcium and vitamin D therapy. Growth in the adoption of specialized endocrinology services and rare disease management is also aiding in driving the growth in the market. Further, increased spending on clinical trials is aiding in the innovation of better therapies for the condition in terms of dosing convenience and disease management.

On August 16, 2024, the FDA approved Ascendis Pharma's Yorvipath (palopegteriparatide), making it the first and only treatment specifically designed to target the underlying hormone deficiency of hypoparathyroidism in adults, a once-daily prodrug engineered to deliver continuous parathyroid hormone exposure over a 24-hour period, arriving just as Takeda prepared to discontinue global manufacturing of Natpara, the only prior hormone replacement option, by the end of 2024.

Hypoparathyroidism Treatment Market Trends

• Rising adoption of recombinant parathyroid hormone replacement therapy displacing conventional supplementation.

• Growing improvement in rare disease diagnosis capability identifying previously undiagnosed patient populations.

• Expanding specialty endocrinology clinic access bringing precision treatment within reach of more patients.

• Increasing patient adherence program investment supporting long-term hormone replacement therapy management.

• Rising thyroidectomy procedure volumes continuing to expand the post-surgical hypoparathyroidism patient population.

U.S. Hypoparathyroidism Treatment Market Overview

The U.S. Hypoparathyroidism Treatment Market was valued at USD 286.30 Million in 2025 and is expected to reach USD 486.80 Million by 2035, growing at a CAGR of 5.45% from 2026-2035.

The growth of the U.S. Hypoparathyroidism Treatment Market can be attributed to increased disease awareness, diagnosis, and presence of sophisticated hormone replacement treatment methods. Increased recognition by physicians and higher utilization of tests such as calcium and parathyroid hormone are enabling early detection of patients who require treatment. Availability of recombinant and long-acting parathyroid hormone treatments is contributing to the increasing range of treatment methods for patients who have failed to respond to standard calcium and vitamin D supplementation therapy. Favorable healthcare system infrastructure, provision of endocrinology services and availability of innovative specialty drugs are adding impetus to the growth of this market.

Ascendis Pharma launched Yorvipath commercially in the United States in the first quarter of 2025, offering patients access through its Ascendis Signature Access Program, which provides treatment journey support and financial assistance services, following the FDA's grant of seven years of orphan drug market exclusivity for the treatment in September 2024.

Hypoparathyroidism Treatment Market Segment Analysis

• By Product Type, Vitamin D Analogue segment dominated the Hypoparathyroidism Treatment Market in 2025 with 39% share; Parathyroid Hormone Replacement segment is the fastest growing segment, registering a CAGR of 9.25% during 2026–2035.

• By Route of Administration, Oral segment dominated the market in 2025 with 73% share; Parenteral segment is the fastest growing segment, registering a CAGR of 8.35% during 2026–2035.

• By Distribution Channel, Retail Pharmacies segment dominated the market in 2025 with 42% share; Online Platforms segment is the fastest growing segment, registering a CAGR of 8.72% during 2026–2035.

By Product Type, Vitamin D Analogue Dominates Hypoparathyroidism Treatment Market; Parathyroid Hormone Replacement to Register Fastest Growth.

Vitamin D Analogue dominated the Hypoparathyroidism Treatment Market in 2025 because such treatment forms serve as a major treatment option for regulating calcium in individuals suffering from reduced parathyroid hormone production. Vitamin D analogues increase calcium uptake through the intestines and maintain blood serum levels of the mineral, hence acting as a part of the conventional treatment. The common use of vitamin D analogues in clinics, the familiarity of the medication, and availability make them in great demand in the treatment market. Moreover, the compatibility with other medications used for hypoparathyroidism makes them lead players of the market.

Parathyroid Hormone Replacement is expected to register the fastest growth due to the fact that it targets the hormone deficiency problem in hypoparathyroidism directly, unlike traditional treatment that uses calcium and vitamin D therapy. Awareness about the number of patients who are not adequately treated with conventional treatment methods is driving the interest in hormone replacement therapy options. The growing awareness and advancement in parathyroid hormone replacement therapies would fuel the adoption in the coming years.

By Route of Administration, Oral Dominates Hypoparathyroidism Treatment Market; Parenteral to Register Fastest Growth.

Oral administration dominated the Hypoparathyroidism Treatment Market in 2025 due to the prevalence of calcium supplementation and vitamin D analogues that are usually administered by an oral route. It is convenient, easy to administer, already established in prescription practices, and suitable for the long-term management of the disease. Patients are able to administer their medication out-of-hospital since these methods do not require constant monitoring, and thus reducing the number of visits required for administration. Availability of oral calcium and vitamin D drugs in pharmacies and physicians' familiarity with these medicines contribute to their usage.

Parenteral administration is expected to register the fastest growth due to increasing popularity of hormone replacement therapies in treatment of hypoparathyroidism in those patients who require advanced methods of treatment and remain inadequate when being under conventional treatments. Injectable method of administration will allow for more effective and controlled administration of medications, which is necessary in systemic hormone replacement therapy. Increasing awareness of physicians about the persistence of symptoms, unstable levels of calcium, and other limitations of conventional therapies will make physicians consider advanced methods of treatment.

By Distribution Channel, Retail Pharmacies Dominate Hypoparathyroidism Treatment Market; Online Platforms to Register Fastest Growth.

Retail Pharmacies dominated the Hypoparathyroidism Treatment Market in 2025 due to their proximity to calcium supplement drugs, Vitamin D analogs, and other drugs used for extended therapy needs. Chronic cases of hypoparathyroidism require constant medication treatment, and therefore, retail pharmacies play an important role in supplying these medications to patients. Additionally, retail pharmacies will help in creating a channel of communication between patients, doctors, and healthcare practitioners. The wide availability, well-established distribution chain, and familiarity of patients with retail pharmacies favor the growing preference for these channels, especially for extended needs.

Online Platforms are expected to register the fastest growth owing to the increased influence of digital health and prescription of long-term medications and supplements. E-Pharmacies can provide convenient ordering of drugs, deliveries to customers' homes, and comparisons of products. Increasing internet usage, growing digital health ecosystem, and enhanced services at online pharmacies will drive this trend. More patient familiarity with e-commerce and convenient ordering of medications will further strengthen online distribution, especially for patients requiring extended hypoparathyroidism treatment.

Regional Analysis

North America Hypoparathyroidism Treatment Market Insights

North America dominated the market with a 39.65% share in 2025. A well-established rare disease diagnosis and advocacy infrastructure, broad specialty pharmaceutical reimbursement coverage, and the concentration of leading biopharmaceutical companies headquartered within the region continue to anchor this leadership position across every major treatment type and product category.

Canada contributes meaningful incremental regional demand through its own rare disease healthcare infrastructure and specialty pharmaceutical reimbursement environment. Continued hormone replacement therapy adoption and specialty clinic expansion among leading companies is expected to keep North America in the lead through the forecast period, even as its growth rate trails the faster-scaling markets developing across Asia Pacific.

Europe Hypoparathyroidism Treatment Market Insights

Europe holds a significant share of the global market, anchored by Germany's substantial rare disease patient population and the region's well-developed specialty pharmaceutical reimbursement framework, which continues to sustain steady demand across every major hypoparathyroidism treatment category.

The United Kingdom, France, and Italy add consistent regional demand as national health systems continue extending hormone replacement therapy access. Continued regional rare disease policy support is expected to sustain steady growth across the broader European market through the forecast period.

Asia Pacific Hypoparathyroidism Treatment Market Insights

Asia Pacific is projected to be the fastest-growing region over the forecast period, registering a CAGR of approximately 8.75%. Rapidly improving rare disease diagnosis capability, expanding specialty endocrinology clinic infrastructure, and rising thyroid surgery volumes across the region's major economies continue to accelerate regional adoption of hypoparathyroidism treatment.

China anchors regional demand through its expanding specialty healthcare infrastructure and growing thyroid cancer diagnosis rates. Japan and South Korea contribute additional regional depth through established endocrinology specialist sectors, while India's rapidly expanding private healthcare sector continues to add meaningful incremental regional growth as rare disease diagnosis capability improves.

MEA and Latin America Hypoparathyroidism Treatment Market Insights

The Middle East and Africa region is supported by growing specialty healthcare infrastructure investment across the United Arab Emirates and Saudi Arabia, where regional governments continue expanding rare disease diagnosis and treatment capacity as part of broader healthcare modernisation strategies.

Latin America is anchored by Brazil, where a growing domestic specialty healthcare sector sustains steady demand for hypoparathyroidism treatment. Mexico contributes further incremental growth as regional rare disease diagnosis and specialty clinic access continue to expand gradually.

Market Dynamics

Growth Drivers: Recombinant Therapy Advancement and Improved Diagnosis

Growth in recombinant treatments is one of the primary drivers as new hormone replacement drugs cater to the deficiency of PTH and provide more treatment options for people who cannot be controlled with standard calcium and active vitamin D therapy. The recent advances in treatment options, such as long-term PTH replacement, are helping the treatment scenario and providing better treatment solutions for hypoparathyroidism.

The increased awareness about rare disease diagnosis is another significant driver, as better knowledge among physicians, biochemical tests, and genetic tests may help identify people who have not been diagnosed yet or misdiagnosed. Improved specialist treatment and disease management are also contributing to treatment adoption. With improved diagnosis and availability of endocrinologist services, an increasing number of people are likely to be managed properly, boosting treatment demand during the forecast period.

Restraints: High Treatment Cost and Supply Constraints

The high cost of the novel hormone replacement therapy will still act as a major constraint since some PTH replacement therapies can end up being far more expensive to treat than traditional treatments using calcium and active vitamin D. The lack of reimbursement in certain markets and the high expense of such a treatment can pose an issue in the accessibility to the drug by those who require it in the long run. The international guidelines still prescribe calcium and active vitamin D as first-line therapies with PTH replacement coming second.

Another constraint lies in the manufacturing and supply issues, which have become common in the pharmaceutical industry, and the hypoparathyroidism is a rare condition with a specific therapy market that is not large enough to support high production capabilities of novel biologic and peptide drugs.

Opportunities: Expanding Diagnosis Capability and Pediatric Indication Development

The development of rare disease diagnostic possibilities creates a significant chance, as an increased level of physician awareness, biochemical, and genetic testing can reveal people who have not been diagnosed yet. The current diagnostics guidelines highlight the importance of repeating the testing of calcium and PTH levels, while genetic testing should be performed in certain cases of non-surgical disease, especially among younger patients or those who have certain syndromes.

The development of indications in pediatrics presents another chance of growth, as the options for treatment of children are still limited compared to adults. Traditional therapy based on calcium and active vitamin D use is the only way for children now, but PTH therapy can be used in case when the traditional treatment is insufficient.

Recent Developments:

• 2024: the FDA approved Ascendis Pharma's Yorvipath (palopegteriparatide), the first treatment specifically designed to target the underlying hormone deficiency of hypoparathyroidism in adults.

• 2024: the FDA granted Yorvipath seven years of orphan drug market exclusivity in the United States for the treatment of hypoparathyroidism in adults.

• 2025: Ascendis Pharma launched Yorvipath commercially in the United States, offering patient access through its Ascendis Signature Access Program.

Hypoparathyroidism Treatment Market Key Players

• Ascendis Pharma A/S

• Takeda Pharmaceutical Company Limited

• Amgen Inc.

• Eli Lilly and Company

• Chugai Pharmaceutical Co., Ltd.

• Entera Bio Ltd.

• Extend Biosciences, Inc.

• Alexion Pharmaceuticals, Inc. (AstraZeneca Rare Disease)

• Ultragenyx Pharmaceutical Inc.

• Amolyt Pharma (AstraZeneca)

• Sun Pharmaceutical Industries Ltd.

• Teva Pharmaceutical Industries Ltd.

• Sanofi S.A.

• Novartis AG

• Bayer AG

• Opko Health, Inc.

• Amryt Pharma plc (Chiesi)

• Fresenius Kabi AG

• Viatris Inc.

• Novo Nordisk A/S

Hypoparathyroidism Treatment Market Report Scope: